This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P U 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P U 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P U 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization.
Introduction
Conventional treatment for nonmassive pulmonary embolism consists of the use of unfractionated heparin or low-molecular-weight heparins (LMWHs) as a 'bridge' for oral anticoagulation therapy [1] . This approach requires 5 days or more of treatment with heparin until the vitamin K antagonists reach therapeutic levels. Treatment with acenocoumarol implies frequent laboratory determinations to adjust the dose, and it interacts with numerous foods and medicines. On the other hand, the use of LMWHs at weight-dependent fixed doses enables attaining predictable levels of anticoagulation without the interactions of acenocoumarol [2, 3] .
Some studies have shown that secondary prevention with LMWHs is just as effective and safe in patients with a diagnosis of pulmonary embolism, and LMWHs have even become the drugs of choice for long-term treatment when the embolism is due to neoplasia [4] [5] [6] . Nevertheless, the majority of patients included in these trials presented deep vein thrombosis (DVT) as a sign of the thromboembolic disease and a significant percentage of patients were excluded under strict criteria [7] . Traditionally, clinicians have treated patients with acute DVT or pulmonary embolism in the hospital. Patients typically receive this initial therapy until they are successfully converted to oral vitamin K antagonist therapy. Although most patients with acute pulmonary embolism remain hospitalized during the initial therapy, some may be suitable for partial or complete outpatient management. Subcutaneously administered LMWHs could replace much oral vitamin K antagonist therapy and facilitate outpatient pulmonary embolism therapy because of their rapid antithrombotic effect, fixed weight-based dose, and the lack of need for daily anticoagulant monitoring.
The purpose of this study was to make a prospective evaluation of the efficacy and safety of enoxaparin as secondary prevention of venous thromboembolism in a consecutive series of patients with acute symptomatic pulmonary embolism. We therefore hypothesized that enoxaparin is as effective and safe as acenocoumarol for secondary prevention of pulmonary embolism, and it is associated with a shorter hospital stay.
Patients
We screened and recruited outpatients presenting with symptoms of acute pulmonary embolism at the Emergency Department of Ramó n y Cajal Hospital, Madrid, Spain. We excluded from the study patients with hemodynamic instability at presentation (defined as cardiogenic shock, systolic blood pressure < 90 mmHg, or need of inotropic support despite blood pressure measurements), those in whom thrombolytic therapy or an inferior vena cava filter was indicated by decision of the attending physician, those with active hemorrhage at the time of diagnosis, known allergy to heparin, impaired renal function (defined as a creatinine clearance < 30 ml/min), pulmonary embolism secondary to active cancer, or inability to follow home treatment with enoxaparin. Eligible patients were required to have pulmonary embolism confirmed by objective testing. The confirming diagnosis required the presence of a high-probability ventilation/perfusion lung scan according to the Prospective Investigation of the Pulmonary Embolism Diagnosis criteria [8] , the presence of an intraluminal filling defect in a pulmonary artery on helical chest computed tomography scan [9] , or the presence of deep vein thrombosis documented by ultrasonography in patients with chest symptoms and a nonconclusive perfusion lung scan. The study was approved by the Institutional Review Board and all patients signed an informed consent form.
Treatment
All patients received initial treatment with enoxaparin (Clexane; Sanofi-Aventis, Madrid, Spain) at a dose of 1 mg/kg twice a day for 5 days. At the time of enrollment, the patients had selected secondary prophylaxis with acenocoumarol or enoxaparin at a dose of 1 mg/kg once a day after being informed of the type of administration and the expected frequency of laboratory monitoring for both medicinal products (with a standardized sheet). For the patients that selected treatment with acenocoumarol, the International Normalized Ratio was usually monitored daily until the therapeutic range had been achieved, then twice or three times weekly for the first weeks, and then once a week or less often, depending on the stability of the results. Patients with a transitory risk factor were treated for at least 3 months, and patients with idiopathic pulmonary embolism were treated for at least 6 months [10] .
Follow-up and study endpoints Since the study was designated to evaluate clinically relevant recurrent thromboembolic events during the first 90 days on treatment, no surveillance for asymptomatic thrombosis was undertaken. Rather, at each visit, clinical events that had occurred since the previous visit were evaluated. Given the open character of the study design, each episode of clinically suspected recurrent thromboembolic event was carefully and systematically documented using objective test methods. Suspected DVT recurrences were evaluated with lower extremity venous compression ultrasonography. Recurrent DVT was defined by the appearance of a new noncompressible vein segment, or a 4 mm or larger increase in the diameter of a thrombus on venous ultrasound, or a new intraluminal filling defect or an extension of a previous filling defect on a venogram [11] . Suspected pulmonary embolism was evaluated with ventilation-perfusion lung scintigraphy testing or pulmonary embolism protocol helical chest computed tomography. The presence of a new pulmonary embolism was defined by a new perfusion scan defect involving 75% or more of a lung segment, or by the presence of a new intraluminal filling defect or an extension of a previous filling defect on helical chest computed tomography. Radiologists who interpreted tests for suspected recurrences were not aware of the details of patient presentation and participation in this study. Major hemorrhage was defined as any bleeding that led to hospitalization or transfusion.
As an index of net clinical benefit, we defined an a priori composite endpoint of recurrent venous thromboembolism, major hemorrhage, and death from any cause.
Statistical analysis
The cumulative incidence of outcome events was described according to the Kaplan-Meier method [12, 13] , and rates were compared with the use of the log-rank test. The dependence between qualitative variables was analyzed using the chi-squared test with Fisher's or Yates' correction, the Mann-Whitney test for continuous variables that do not follow a normal distribution, and the Student's t-test for those with normal distribution.
The significance of a number of clinical variables for the risk of either thromboembolic recurrence or major bleeding was tested by fitting a bivariate proportional hazards model.
Results
A total of 464 patients had objectively confirmed acute symptomatic pulmonary embolism between January 2003 and December 2005. Fifty-three patients were excluded because of active cancer at the time of diagnosis and 10 patients because of hemodynamic instability at presentation. Since 21 patients were lost to follow-up, the evaluable population consisted of 94.8% (380 patients) of eligible patients with acute pulmonary embolism.
One hundred and ninety-nine patients (52%) selected treatment with acenocoumarol. As regards their clinical presentation, patients treated with enoxaparin more often had tachycardia, and recent immobilization was observed significantly more often (Table 1) . There was no imbalance in the other baseline characteristics between the two groups.
During the 3-month treatment period, four patients (2.2%) treated with enoxaparin experienced objectively confirmed recurrent thromboembolism (95% confidence interval, 0.1-4.3%), none of them fatal. There were six recurrences (3.0%) among the patients assigned to receive acenocoumarol (95% confidence interval, 0.7-5.6%) (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P ¼ 0.64), three of them fatal. There were nine hemorrhages in the group of patients treated with enoxaparin (5.0%), and 11 (5.5%) in the rest of the series (hazard ratio, 1.11; 95% confidence interval, 0.46-2.69; P ¼ 0.81). Patients treated with enoxaparin were hospitalized for significantly fewer days than patients treated with acenocoumarol (11 versus 16 days, P ¼ 0.0001) ( Table 2) . Table 3 presents the risk of recurrence depending on the age, sex, body mass index, immobilization, the presence of DVT at the time of enrollment, and the troponin values. Only the presence of DVT was associated with recurrences during the study period (hazard ratio, 8.4; 95% confidence interval, 1.1-67.6; P ¼ 0.04). Table 4 presents the risk of major bleeding during the study period. Neither sex, age equal to or older than 75 years, body mass index of 22 kg/m 2 or less, or creatinine of at least 2 mg/dl were associated with a higher risk of major hemorrhage.
After performing Kaplan-Meier analysis, there was no difference in the composite endpoint rate between the patients in each treatment group during the follow-up period (P ¼ 0.13) (Fig. 1) .
Discussion
Several studies have compared the LMWHs with oral anticoagulants for the long-term prevention of thromboembolic disease [3] [4] [5] . A meta-analysis of these studies found a reduction of 30% in the recurrence and of 66% in hemorrhages in the group treated with LMWH during the active treatment phase, compared with the group treated with oral anticoagulants [7] . The authors of the study suggested that these differences could be due to the poor quality of the treatment with oral anticoagulants. When performing clinical trials, however, it is common to find a greater degree of suitability of oral anticoagulation than in clinical practice. A review by the Cochrane Library demonstrated that both treatments were equally efficient in the secondary prevention of thromboembolic vein disease, but that LMWHs were possibly safer [14] . In our experience, treatment with enoxaparin was just as effective and safe as treatment with acenocoumarol in a consecutive series of patients with a diagnosis of hemodynamically stable pulmonary embolism.
Treatment with subcutaneous LMWH without laboratory controls has simplified outpatient treatment of proximal DVT [15, 16] . In our series, the hospital length of stay for patients treated with enoxaparin was significantly shorter than that of patients treated with acenocoumarol. This form of secondary prevention may simplify the Enoxaparin to prevent pulmonary embolism Jimé nez et al. 175 Data presented as n (%) or n (95% confidence interval).
performance of future clinical trials for home treatment of patients with hemodynamically stable pulmonary embolism [17] .
From the beginning of the study we decided to use a dose of enoxaparin intermediate between the preventative dose and the full therapeutic dose. Studies performed to date have used preventative doses (4000 U/day) [18, 19] through to therapeutic doses (200 U/kg once a day) [20] . A recent meta-analysis suggested that the intermediate doses could be safest, most efficient and most economic [7] . Although we did not obtain anti-activated factor X levels, the percentage of thromboembolic recurrences was similar to that observed in a recent trial in which a dose of 1.5 mg/kg enoxaparin once a day was used [21] .
Our validation study has several strengths. First, our experience could be a more suitable reflection of usual clinical practice, as clinical trials exclude a significant number of patients. For example, 81% of evaluable patients in the study by Kucher et al. [21] were excluded for different reasons. Our series included a broad spectrum of symptomatic pulmonary embolism patients, including 33% of high-risk patients identified by elevated troponin levels. Second, all patients in our series presented a confirmed diagnosis of pulmonary embolism, whereas the majority of studies published to date were carried out on patients with a diagnosis of DVT. Third, cancer patients were excluded from our study, as different trials have clearly shown that LMWHs are the treatment of choice in patients with pulmonary embolism and cancer [5, 22] .
There are several limitations to our study that should be acknowledged. First, in contrast to a randomized controlled clinical trial, no experimental intervention was imposed. In this way, any conclusions have to be drawn cautiously. Both groups of treatment, however, were well balanced in most biological and clinical characteristics. Immobilization was significantly more frequent in patients treated with enoxaparin. Immobile patients with acute venous thromboembolism may have a significantly poorer clinical outcome, in terms of the incidence of fatal pulmonary embolism and bleeding complications [23] . Since this potential bias may lead to more conservative estimates of risk for patients treated with acenocoumarol, it adds to the robustness of this study's findings. Second, our study did not make a pharmacoeconomic analysis. Treatment with enoxaparin is more expensive than treatment with acenocoumarol. The need for regular laboratory controls in patients treated with acenocoumarol and the greater number of hemorrhagic events in this group of patients, however, could balance the costs of both forms of treatment. This hypothesis should be tested in well-designed clinical trials.
In conclusion, our data confirm the efficacy and safety of enoxaparin in the secondary prevention of pulmonary embolism in usual clinical practice. This form of treatment could be especially indicated in cases with difficulties for outpatient monitoring of acenocoumarol or in patients in which early discharge or even home treatment is expected. Creatinine ! 2 mg/dl 1.04 (0.14-7.77) 0.97 Cumulative risk of the composite study endpoint of recurrent venous thromboembolism, major bleeding, or death from any cause.
